Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Breast Neoplasms 47Neutropenia 26Lymphoma 25Lymphoma, Non-Hodgkin 12Lymphoma, Large B-Cell, Diffuse 12Neoplasms 11Sarcoma 9Lymphoma, Follicular 9Ovarian Neoplasms 8Lymphoma, Mantle-Cell 8Leukemia 8Hodgkin Disease 8Carcinoma, Non-Small-Cell Lung 8Lung Neoplasms 7Leukemia, Lymphocytic, Chronic, B-Cell 7Triple Negative Breast Neoplasms 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Multiple Myeloma 5Lymphoma, B-Cell, Marginal Zone 5Chemotherapy-induced Neutropenia 5Rhabdomyosarcoma 4Neoplasm Metastasis 4Lymphoma, Large-Cell, Immunoblastic 4Burkitt Lymphoma 4Waldenstrom Macroglobulinemia 3Urinary Bladder Neoplasms 3Testicular Neoplasms 3Sarcoma, Synovial 3Prostatic Neoplasms 3Neurofibrosarcoma 3

Interventions

tofacitinib 6ibrutinib 6Imatinib Mesylate 5ofatumumab 4Rituximab 4nilotinib 3ruxolitinib 2bosutinib 2asciminib 2Pentostatin 2Oxycodone 2Naloxone 2KW-2478 2Dasatinib 2ziconotide 1sodium luminolate 1posaconazole 1pegfilgrastim 1oblimersen 1obinutuzumab 1montelukast 1mocetinostat 1lonafarnib 1ixekizumab 1fludarabine 1fenebrutinib 1canakinumab 1baricitinib 1abexinostat 1Voriconazole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Bronchiolitis Obliterans Syndrome × pegfilgrastim × Clear all
NCT04294641 2026-01-23

Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
10 enrolled 15 charts
Other hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡